

QUARTERLY ACTIVITIES & CASHFLOW REPORT

PERIOD ENDING 30 SEPTEMBER 2026

BRISBANE, AUSTRALIA, 29 October 2026: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**), a supplier of chemicals and advanced material solutions to the Lithium ion Battery (LiB) and Life Sciences diagnostic markets, is pleased to provide its Activities Update and Appendix 4C Quarterly Cash Flow Report for the period ended 30 September 2026 (the “**Quarter**”). All financial results are in Australian dollars and unaudited.

The September 2026 Quarter focused on commercial execution, with increased engagement with sales qualified potential customers undertaking technical product validations across the Advanced Battery Technologies (ABT) and Life Sciences (LS) businesses.

During the Quarter, the Company executed a Strategic Collaboration and Sales Agreement with Xerabrid Corporation, launched Anteo C™, signed a next-generation battery design and prototyping supply agreement with Airspeeder; soft launched its AnteoBind™ NXT CLIA Kits and prototype AnteoBind™ NXT activated ELISA plates at ADLM 2026 in the USA; progressed its CLIA collaboration with a large global life sciences company and received A\$1.9 million under the Research and Development Tax Incentive, with cash and cash equivalents of A\$11.0 million at 30 September 2026.

HIGHLIGHTS

Advanced Battery Technologies (ABT)

- Customer evaluations of AnteoTech’s performance additive portfolio, comprising Anteo X™, Anteo S®, Anteo C™ and SiMRAX, continued across Asia and the US. This included delivery of 40L each of Anteo S® and Anteo C™ to two customers for scale-up and manufacturing trials, and an indicative volume pricing request from a US customer planning to trial 30 L of SiMRAX in several hundred demonstration cells.
- A binding Strategic Collaboration and Sales Agreement (SCSA)¹ was executed with Xerabrid Corporation around combining Anteo S™ with Xerabrid’s ceramic-coated separator technology. Seven potential customers have requested samples, including up to 1,000 metres of roll-to-roll manufactured separator material, with delivery now expected before the end of 2026.
- Ultranode™ 95 cylindrical battery cells were successfully assembled, formed and tested at the Battery Innovation Centre in the US. Further optimisation of the 18650 cells is underway, with the aim being supply of prototype cells to prospective customers for evaluation.
- A next-generation battery design and prototyping supply agreement was signed with Airspeeder Pty Ltd², providing AnteoTech with an opportunity to demonstrate Ultranode™ 95 in electric vertical take-off and landing (eVTOL) applications for Team Australia.

¹ ASX Announcement 20 August 2026

² ASX Announcement 8 September 2026

- Negotiations continued on two non-exclusive Ultranode™ 95 Joint Development Agreements with US battery manufacturers and technology partners targeting defence and drone applications.
- Ultranode™ 70 achieved the agreed cycle life performance metric in Wyon AG commercial form-factor cells, completing 500 cycles at 70% capacity retention. Wyon is in the process of identifying and engaging with potential end customers.
- Post period end, ARENA³ extended the initial grant milestone deadline by six months, from 13 November 2026 to 13 May 2027, providing additional time for strategic discussions.

Life Sciences (LS)

- Recurring revenue continued under the five-year take-or-pay supply agreement with the Serum Institute of India, with an A\$134,138 AnteoBind™ shipment delivered on 7 July 2026 and recognised as FY2027 revenue. SII continues to evaluate prototype AnteoBind™ activated ELISA plates.
- The initial stage of the collaborative chemiluminescent immunoassay (CLIA) development product program with a large global life sciences company was completed on schedule, with the next stage of work agreed and underway.⁴
- AnteoBind™ NXT CLIA Kits and prototype activated ELISA plates were introduced at ADLM 2026 in the US. The event generated new sales opportunities, follow-up meetings and sample requests, with leads generated at ADLM tripling the Life Sciences Pipeline.⁵
- Independent third-party validation of AnteoBind™ NXT has been commissioned with testing organisations in the US and UK, covering lateral flow, multiplex and CLIA applications.
- The Life Sciences business expanded its US business development network on a trial basis following ADLM 2026, supporting engagement with large life sciences companies.
- A webinar featuring Professor Amit Asthana of India's National Institute of Pharmaceutical Education and Research (NIPER) was held on 6 October 2026, showcasing AnteoBind™ applications in lateral flow, paper-based and electrochemistry-based immunodiagnostics. Follow up engagement is underway.
- The Life Sciences team is preparing to attend MEDICA 2026 in Düsseldorf, Germany, from 16–19 November 2026, to progress customer engagement and sales opportunities.

Corporate

- The Company received A\$1,905,639 under the Research and Development Tax Incentive, relating to eligible FY2026 R&D expenditure across both business units.⁶

³ ASX Announcement 29 October 2024

⁴ ASX Announcement 1 July 2026

⁵ ASX Announcement 24 August 2026

⁶ ASX Announcement 29 September 2026

- A total of 5,386,569 fully paid ordinary shares were issued to eligible employees under the Equity Incentive Plan in settlement of FY2026 Short-Term Incentive outcomes, preserving cash.⁷
- Mr Scott Waddell resigned as Chief Financial Officer and Company Secretary, effective 4 December 2026⁸. Post period-end, Mr Luke Oxenham was announced as his successor, with an orderly transition underway.
- The Company closed the Quarter with A\$11.0 million in cash and cash equivalents, including A\$5.5 million held on term deposit, and no bank debt, excluding lease and asset-finance liabilities.
- The Company's Annual General Meeting is scheduled for 10 November 2026 at 10:00am (AEST) in Brisbane.⁹

AnteoTech Managing Director & Chief Executive Officer Merrill Gray commented:

"The September 2026 Quarter focused on deeper customer engagement and progressing sales conversion across both business units, supported by our Sales and Marketing resources and systems. The execution of the Xerabrid SCSA, our agreement with Airspeeder, expanded US engagement by the Life Sciences team and new product offerings have provided additional routes to market".

"Customer interest across both businesses continues to grow, with more samples under evaluation and commercial sales discussions underway. Our focus remains on supplying samples for evaluation, supporting customer testing and converting evaluations into sales through the December 2026 Quarter and beyond".

"The receipt of our A\$1.9 million R&D Tax Incentive refund has further strengthened our balance sheet as we progress through FY2027, with a clear focus on sales conversion."

⁷ ASX Announcements 1 September 2026 and 16 September 2026

⁸ ASX Announcement 9 September 2026

⁹ ASX Announcement 8 September 2026 and 7 October 2026

A. ADVANCED BATTERY TECHNOLOGIES (ABT)

1. ANTEO S® – MARKET DEVELOPMENT

During the Quarter, AnteoTech progressed market development for Anteo S®, with samples under evaluation by major separator manufacturers in South Korea, the US, Japan and other parts of Asia.

One potential customer received 40 L of Anteo S® following multiple rounds of smaller sample evaluations. This represents the largest single-volume sample delivery of Anteo S® to date and will support pilot-scale trials and evaluation of additional applications with the customer’s end users.

Customer trials are expected to conclude by the end of 2026, with preparations for potential commercial supply, including cost effective volume production, underway.

2. XERABRID – COLLABORATION PROGRESSION AND MARKET DEVELOPMENT

AnteoTech signed a binding Strategic Collaboration and Sales Agreement (SCSA) with Xerabrid Corporation, establishing a commercial framework for the joint development, marketing, manufacture and potential commercial sale of a high-performance ceramic-coated separator (CCS) incorporating Anteo S®.

The key milestones and indicative timelines under the SCSA are outlined in Figure 1 below.

Mutually Agreed Next SCSA Steps




Figure 1: Mutually agreed next steps and indicative timeline under the Xerabrid SCSA.

Joint marketing activities have generated inbound enquiries from battery manufacturers and device OEMs, with several potential customers requesting samples of the combined Anteo S®/Xerabrid separator product for evaluation. Initial sample shipments are now expected before the end of 2026.

Development of an ultra-thin ceramic coated separator (CCS), with a target total thickness of $\sim 7\text{ }\mu\text{m}$, has commenced.¹⁰ Details of the design were presented at The Battery Show North America in October 2026.

3. ANTEO C™ – MARKET DEVELOPMENT

Anteo C™, the newest addition to the Company's performance additive portfolio, generated interest from potential customers during the Quarter through targeted marketing and engagement across Europe and the US.

In Asia, one customer has received a cumulative volume of 45 L of Anteo C™. They are understood to be completing product development processes, which if successful, could be deployed by mid next year. Commercial supply discussions have commenced.

4. SiMRAX – MARKET DEVELOPMENT

Customer evaluation of SiMRAX, jointly developed with US-based Black Diamond Structures (BDS), a specialist in single-walled carbon nanotube (SWCNT) dispersion and formulation technology, progressed during the Quarter.

SiMRAX is being evaluated by defence battery and silicon anode technology manufacturers, with testing demonstrating improved cycle life and potential reductions in battery raw material costs. Evaluations cover silicon anode applications for defence batteries and emerging lithium-sulphur-based cathode technologies.

Lithium-sulphur cathodes have been identified as an additional potential application for SiMRAX, as the product simultaneously tackles two of the major short-comings of these cathode chemistries. The SCWNTs provide electrical connectivity (sulphur is an electrical insulator) and Anteo X® increases the cohesion of the cathode coating given sulphur's volume expansion upon lithiation.

Testing by a lithium-sulphur technology company demonstrated that SiMRAX could be incorporated into existing coating processes, achieving comparable or improved cathode coating quality and increased capacity retention relative to control formulations. Following these results, additional samples have been requested for scale-up testing.

Separately, a US-based consumer electronics original equipment manufacturer (OEM) has requested a quotation for 30 L of SiMRAX for product scale-up trials involving the manufacture of several hundred demonstration pouch cells.

5. ULTRANODE™ 95 – FIRST 18650 CYLINDRICAL CELLS SUCCESSFULLY ASSEMBLED AND TESTED AT BIC

During the Quarter, AnteoTech progressed its Ultranode 95™ cell demonstration and prototyping program at the Battery Innovation Centre (BIC) in Indiana, USA.

¹⁰ ASX Announcement 14 October 2026

A first of its kind 18650 cylindrical cell incorporating Ultranode™ 95 high-silicon anode technology and high-nickel cathode electrodes was successfully assembled, formed and tested at BIC, as shown in Figure 2 below).



Figure 2: First of its kind 18650 cylindrical cell using Ultranode™ 95 technology

Cylindrical cells are widely used in US defence and drone applications, making this an important step in demonstrating that compatibility of Ultranode™ 95 technology with this cell format.

Further work is underway at BIC to optimise cell performance. Subject to achieving the required performance parameters, AnteoTech intends to progress engagement with battery manufacturers and OEMs, including potential prototype trials.

6. ULTRANODE™ 95 DRONE MARKET – JDA NEGOTIATIONS CONTINUE

Two non-exclusive Ultranode™ 95 Joint Development Agreements (JDAs) remain under negotiation with battery manufacturers supplying, or seeking to supply, the US defence and broader drone markets.

Both potential partners have received roll-to-roll (R2R) Ultranode™ 95 samples, with testing either underway or scheduled in accordance with their internal evaluation programs.

The successful assembly, formation and testing of Ultranode™ 95 in 18650 cylindrical cells at BIC provides an additional technical milestone to support these ongoing discussions.

7. AIRSPEEDER – SUPPLY AGREEMENT

During the Quarter, AnteoTech signed an agreement with Airspeeder Pty Ltd to supply next-generation LiB designs and prototypes for AirSpeeder Team Australia, incorporating Ultranode™ 95 technology. AnteoTech has exclusivity over the supply of battery designs and prototypes to Team Australia¹¹.

As consortium lead, AnteoTech will bring together expertise in high-energy battery chemistries, cell design, battery management systems, and battery pack design and prototyping to support the development of advanced battery technology for eVTOL aircraft.

Discussions with potential consortium participants are progressing.



Figure 3: Airspeeder Team Australia eVTOL

8. ULTRANODE™ 70 – WYON AG CELL LEVEL EVALUATION OUTCOMES

During the Quarter, Wyon AG completed its evaluation of Ultranode™ 70 commercial form-factor battery cells. Testing demonstrated that Ultranode™ 70 achieved the more than 500 cycles at 70% capacity retention, meeting the performance target agreed under the Wyon relationship.

These results represent the first real-world demonstration and validation of Ultranode™ technology in commercial form-factor cells by an established battery manufacturer.

The Company continues to explore opportunities with Wyon for the applications of its technology in medical device batteries and miniature consumer products. No specific end customer has been identified at this stage.

9. SALES AND MARKETING AND SILICON SUPPLY CHAIN

Post period end the CEO and ABT team attended The North America Battery Show in Detroit, as part of the Austrade Team Australia delegation. A total of 19 pre-arranged meetings took place with a further 20 new customers engaged with/acquired and requesting samples for evaluation which are underway.

¹¹ ASX announcement 8 September 2026

AnteoTech also participated in the Advanced Materials & Battery Council (AMBC) 2026 Summit held in Brisbane in October. In addition, a services agreement with an Australian silicon supplier was signed, for paid work to take place by the ABT team (\$66,000) in relation to assessing the company's materials' suitability for use in Ultranode™. While AnteoTech's focus is on securing low cost supply chain options in the US to support the Ultranode™ JDAs being pursued, this silicon supply option sits under the ITAR-exempt partner/AUKUS exemption 2024 pathway.

B. LIFE SCIENCES (LS)

1. SERUM INSTITUTE OF INDIA – CONTINUED SALES

AnteoTech continued to supply the Serum Institute of India (SII) under its five-year take-or-pay agreement. An A\$134,138 shipment of AnteoBind™, delivered on 7 July 2026, was recognised as FY2027 revenue.

A further order under the agreement is expected before the end of 2026. SII is also continuing its evaluation of prototype AnteoBind™ NXT activated ELISA plates.

2. CLIA PRODUCT DEVELOPMENT PROGRAM – NEXT STAGE OF WORK AGREED

On 1 July 2026, AnteoTech announced the completion of the initial stage of its collaborative chemiluminescent immunoassay (CLIA) product development program with a large global life sciences company. The program is evaluating the suitability of AnteoBind™ NXT activated magnetic particles for use in large-scale, high-throughput automated CLIA diagnostic platforms.

The next stage of work has been agreed and involves further in-house development activities by AnteoTech, with magnetic bead supply offered to support the soft launch of its AnteoBind™ NXT CLIA kits. A further phase of collaborative work is anticipated before the end of 2026.

AnteoTech has also explored potential market entry pathways through regional distribution partners in South Korea, Japan and India. However, establishing a partnership with a well-established global CLIA market participant remains the Company's preferred commercialisation strategy.

The global CLIA market was estimated at approximately US\$13 billion in 2024, with forecast to grow at approximately 6% CAGR through to 2029. Successful market entry would expand the immunoassay market opportunities available to AnteoTech.

3. ADLM 2026 – CLIA KIT SOFT LAUNCH AND LIFE SCIENCES PIPELINE EXPANSION

The Life Sciences team attended ADLM 2026 in Anaheim, California from 26–30 July 2026, one of the world's largest diagnostics and laboratory medicine conferences. During the event, AnteoTech soft launched its AnteoBind™ NXT CLIA Kits, which combine magnetic particles from selected suppliers with AnteoBind™ NXT activation chemistry, buffers and optimised activation protocols.

Leads generated at ADLM 2026 tripled the Life Sciences sales pipeline in overall lead terms. The AnteoTech booth received more than 80 visits, with subsequent engagement including 18 sales-

qualified follow-up meetings, seven AnteoBind™ NXT sample requests and five activated ELISA plate requests.

Several longstanding contacts re-engaged with AnteoTech to recommence or expand activities. Discussions also commenced with particle manufacturers, diagnostic equipment manufacturers and diagnostic contract manufacturers in the US, Japan and the UK regarding potential collaboration opportunities.



Figure 4: AnteoTech Life Sciences booth at ADLM 2026.

4. INDEPENDENT VALIDATION, ELISA PLATES AND JAPAN

AnteoTech has engaged with organisations in the US and UK regarding independent third-party validation of AnteoBind™ performance in lateral flow, multiplex and CLIA applications.

The Company is also progressing the development of prototype AnteoBind™ activated ELISA plates, designed to provide a lower-cost alternative to premium high-binding plates while maintaining comparable assay performance. Validation activities are underway with multiple plate manufacturers.

In Japan, AnteoTech distributor, Cosmo Bio Co., Ltd (TSE: 3386), appointed in May 2026, continued to support existing and prospective customers during the Quarter.

5. MARKETING AND UPCOMING ENGAGEMENT

On 6 October, AnteoTech hosted a webinar featuring world renowned Professor Amit Asthana of the National Institute of Pharmaceutical Education and Research (NIPER) in India. The webinar showcased AnteoBind™ applications in lateral flow, paper-based and electrochemical immunodiagnosics. The Company's Life Sciences business development facilitator and distributor in India are supporting follow-up engagement with attendees.

The Life Sciences team is preparing to attend MEDICA 2026 in Düsseldorf, Germany from 16–19 November 2026. Pre-arranged meetings with companies already evaluating AnteoBind™ NXT, together with newly qualified leads, will focus on progressing potential customers through the sales pipeline.

AnteoTech continues to pursue commercial opportunities across four detection platforms outlined in Figure 6, representing an estimated combined market size of approximately US\$90 billion annually^{12,13}




Figure 5: Invitro Diagnostic Markets AnteoTech participates in.

C. CORPORATE AND FINANCIALS

1. RESEARCH AND DEVELOPMENT TAX INCENTIVE REFUND

On 29 September 2026, the Company received A\$1,905,639 in cash from the Australian Taxation Office under the Research and Development Tax Incentive. This was received for eligible Australian R&D expenditure across its Advanced Battery Technologies and Life Sciences businesses during FY2026.

The refund strengthens the Company's cash position and provides additional funding to support commercialisation activities.

2. FY2026 FINANCIAL REPORTING AND ANNUAL GENERAL MEETING

AnteoTech released its Appendix 4E and unaudited preliminary financial statements on 31 August 2026.

On 16 September 2026, in accordance with Listing Rule 4.3D, the Company announced a non-cash accounting adjustment relating to the de-recognition of the lease make-good provision for its 26 Brandl

¹² Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company

¹³ ASX Announcement 23 October 2026

Street premises. The adjustment was recognised against the carrying amount of the related right-of-use asset consistent with AASB Interpretation 1 and AASB 16 Leases.

The FY2026 Annual Report, Corporate Governance Statement and Appendix 4G were released on 28 September 2026. Managing Director and CEO Merrill Gray subsequently presented the FY2026 financial results and business update to investors via webinar on 30 September 2026.

The Company's Annual General Meeting is scheduled for 10:00am (AEST) on Tuesday, 10 November 2026, at Rydges South Bank, Brisbane. The Notice of Meeting was released on 7 October 2026.

3. SECURITIES ISSUED AND SECURITIES TRADING POLICY

Following the FY2026 annual performance review, the Board resolved that 70.9% of Company KPIs had been achieved and resolved to settle the majority of Short-Term Incentive (STI) outcomes in shares to preserve cash.

On 15 September 2026, AnteoTech issued 5,386,569 fully paid ordinary shares to eligible employees under the Equity Incentive Plan. The proposed issue of STI shares to the Managing Director and CEO remains subject to shareholder approval at the Annual General Meeting.

During the Quarter, the Company also issued 5,700,000 unquoted options to the Chief Financial Officer on 17 July 202, ,exercisable at A\$0.0375 and expiring on 19 August 2029.

A further 8,758,000 unquoted long-term incentive options were issued to senior staff on 23 September 2026, exercisable at A\$0.0375 and expiring on 22 September 2030, subject to 60-day VWAP hurdles of A\$0.0375 and A\$0.05.

A total of 73,251,921 unquoted options, exercisable at price A\$0.064, expired unexercised on 13 September 2026.

The Company adopted an updated Securities Trading Policy on 26 August 2026.

4. CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

On 9 September 2026, Mr Scott Waddell tendered his resignation as Chief Financial Officer and Company Secretary to pursue other business interests, effective 4 December 2026.

Post period-end, on 28 October 2026, AnteoTech announced the appointment of Mr Luke Oxenham as Chief Financial Officer and Company Secretary, commencing 23 November 2026. An orderly transition is underway.

5. CASH AND EXPENDITURE

As at 30 September 2026, the Company had cash and cash equivalents of A\$11.0 million, including A\$5.5 million held on a six-month term deposit maturing on 18 December 2026. The Company had no bank debt, excluding lease and asset-finance liabilities.

During the Quarter, customer receipts totalled A\$200,134, including A\$134,138 from the Serum Institute of India relating to the July 2026 shipment.

The Company also received A\$1,905,639 under the R&D Tax Incentive (Appendix 4C, item 1.7), resulting in net operating cash outflows of A\$27,932 for the quarter.

A detailed summary of cash flows is provided in the accompanying Appendix 4C Quarterly Cash Flow Report.

Business Expenses	A\$'000
Research and Development	187
Staff, Admin and Corporate	1,647
Other	357
Total (excluding Revenue)	2,191

Capital Expenses	A\$'000
Plant and Equipment	19
Intellectual Property	116

6. ASX LISTING RULE 4.7C.3 DISCLOSURE

During the Quarter, A\$161,000 was paid to related parties and their associates, as reported in Item 6.1 of the Appendix 4C, comprising directors' fees and the Managing Director and CEO's remuneration.

D. LOOKING FORWARD

For the December 2026 Quarter and remainder of FY2027, AnteoTech's primary focus remains on converting customer evaluations into sales, expanding the sales pipeline and securing strategic partnerships across its Life Sciences and Advanced Battery Technologies businesses.

A. LIFE SCIENCES

The LS business will continue to progress and qualify leads generated from ADLM 2026 and MEDICA 2026, while expanding its marketing reach across international markets.

Priorities include: commencement of independent third-party validation programs, validating Lateral flow and CLIA performance improvements through AnteoBind™ NXT, as set out in the White Papers published over the past twelve months. The Company is looking at attending the Biotech & Life Sciences Exhibition/World Health Expo in Dubai in January 2027 and will attend BioAsia in India again in early 2027.

B. ADVANCED BATTERY TECHNOLOGIES

The ABT business, working in collaboration with Xerabrid, is focussed on CCS samples despatch to the seven international manufacturers and OEMs, ultrathin high performance CCS design and manufacture and supporting sample testing and securing sales orders across potential customers. Broader sales of Anteo S™ will also continue to be a focus. Progression of the two Ultranode™ 95 JDA negotiations towards execution will continue.

In addition, the team expects to build the Airspeeder Team Australia next generation battery development consortium.

For Anteo C, the Company will continue to support customer evaluations in South Korea (via Kangshin) with interest expanding in India and the US and work towards securing commercial supply agreements for volume to take place.

Good progress is also beginning to be made with SiMRAX. The Company will work with BDS to convert current customer trials into sales.

C. CORPORATE

The Company will hold its Annual General Meeting on 10 November 2026, engage with strategic partners in relation to the ARENA grant and beyond continue work on the Company's new website, and the Company will maintain financial discipline while supporting sales pipeline conversion.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

– ENDS –

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, MD/CEO, on +61 7 3219 0085

For further information, please refer to our website www.anteotech.com

About AnteoTech – (ASX: ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ and our Collector foil primer coating performance additive Anteo C through to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable chemicals and materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' and other immunoassay diagnostic tests such as Chemiluminescence immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) plates, AnteoBind™ NXT enables faster, more reliable and more accurate test results wherever they are needed.

AnteoTech – Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails – visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will",

“believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risks and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AnteoTech Ltd

ABN

75 070 028 625

Quarter ended ("current quarter")

30 September 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	200	200
1.2 Payments for		
(a) research and development	(187)	(187)
(b) product manufacturing and operating costs	(4)	(4)
(c) advertising and marketing	(156)	(156)
(d) leased assets/occupancy	(183)	(183)
(e) staff costs	(1,066)	(1,066)
(f) administration and corporate costs	(581)	(581)
1.3 Dividends received (see note 3)		
1.4 Interest received	57	57
1.5 Interest and other costs of finance paid	(26)	(26)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	1,906	1,906
1.8 Other (PPL wages)	12	12
1.9 Net cash from / (used in) operating activities	(28)	(28)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(19)	(19)
(d) investments		
(e) intellectual property	(116)	(116)
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(135)	(135)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(41)	(41)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	(41)	(41)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	11,201	11,201
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(28)	(28)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(135)	(135)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(41)	(41)
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of period	10,997	10,997

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,497	5,701
5.2	6-month Term deposit	5,500	5,500
5.3	Bank overdrafts		
5.4	Other		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,201	11,201

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	161
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities	0	0
7.5	Unused financing facilities available at quarter end		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(28)
8.2	Cash and cash equivalents at quarter end (item 4.6)	10,997
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	10,997
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	392
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Authorised by the board
Scott Waddell
Company Secretary
29 October 2026

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.